Clinical Trials Sponsored by Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON)

Total 33 results

Stichting Hemato-Oncologie voor Volwassenen Nederland

Not yet recruiting

FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM) (HOVON174MM)

Multiple Myeloma
Stichting Hemato-Oncologie voor Volwassenen Nederland

Recruiting

REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)

CLL/SLL

Netherlands, Belgium, Denmark
Stichting Hemato-Oncologie voor Volwassenen Nederland

Active, not recruiting

Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM (HO147SMM)

Smouldering Myeloma

Netherlands, Norway, Czechia, Italy
Stichting Hemato-Oncologie voor Volwassenen Nederland

Active, not recruiting

The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL (HO151DLBCL)

NHL | DLBCL

Netherlands, Belgium
Stichting Hemato-Oncologie voor Volwassenen Nederland

Withdrawn

Study to Assess an Interphase Cycle With Flotetuzumab. (HOVON162AML)

AML

Netherlands
Stichting Hemato-Oncologie voor Volwassenen Nederland

Not yet recruiting

Zanubrutinib in Primary Cold Agglutinin Disease (HOVON169CAD)

Lymphoma

Norway, Netherlands, Denmark, Belgium
Stichting Hemato-Oncologie voor Volwassenen Nederland

Active, not recruiting

DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL (HO152)

Lymphoma, B-Cell | Non Hodgkin Lymphoma | High-grade B-cell Lymphoma | MYC Translocation | BCL-2 Translocation

Netherlands, Belgium
Stichting Hemato-Oncologie voor Volwassenen Nederland

Active, not recruiting

A National Study for Blood Based Response Monitoring of B-cell Lymphoma Patients (HO902DLBCL)

NHL

Netherlands
Stichting Hemato-Oncologie voor Volwassenen Nederland

Completed

Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia

United Kingdom
Stichting Hemato-Oncologie voor Volwassenen Nederland

Recruiting

A Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine in Adult Patients With Newly Diagnosed AML (HO171)

AML, Adult

Netherlands
Stichting Hemato-Oncologie voor Volwassenen Nederland

Recruiting

Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse (HOVON 136 NHL)

DLBCL

Netherlands
Stichting Hemato-Oncologie voor Volwassenen Nederland

Active, not recruiting

Blinatumomab Added to Prephase and Consolidation Therapy in Precursor B-acute Lymphoblastic Leukemia in Adults. (HOVON146ALL)

ALL, Adult

Netherlands, Belgium
University of Ulm
Stichting Hemato-Oncologie voor Volwassenen Nederland

Recruiting

Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2

Acute Myeloid Leukemia | Myelodysplastic Syndromes

Germany
Stichting Hemato-Oncologie voor Volwassenen Nederland
Nordic Lymphoma Group

Active, not recruiting

CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD.

CLL

Netherlands, Denmark
Stichting Hemato-Oncologie voor Volwassenen Nederland
Danish Lymphoma Group

Recruiting

Tislelizumab, Gemcitabine and Cisplatin for R/R Hodgkin Lymphoma Followed by Tislelizumab Consolidation in Patients in Metabolic Complete Remission (HOVON164HL)

Hodgkin Lymphoma

Netherlands, Belgium, Denmark
University Medical Center Groningen
Stichting Hemato-Oncologie voor Volwassenen Nederland

Recruiting

Comparison of Point-of-care Produced CAR T-cell With Commercial CAR T-cells in Patients With R/R LBCL (HOVON161)

NHL | DLBCL - Diffuse Large B Cell Lymphoma

Netherlands
Stichting Hemato-Oncologie voor Volwassenen Nederland
Nordic CLL Study Group

Active, not recruiting

A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations

Chronic Lymphocytic Leukemia in Relapse | Chronic Lymphocytic Leukemia in Remission

Netherlands, Belgium, Denmark, Finland, Norway, Sweden
Stichting Hemato-Oncologie voor Volwassenen Nederland
CTI BioPharma; Dutch Cancer Society

Active, not recruiting

Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF) (HOVON134MF)

Myelofibrosis

Netherlands, Belgium
Stichting Hemato-Oncologie voor Volwassenen Nederland
Swiss Group for Clinical Cancer Research

Active, not recruiting

Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS Patients (HO155)

AML/MDS

Netherlands, Belgium, Germany, Switzerland
University College, London
Cancer Research UK; Stichting Hemato-Oncologie voor Volwassenen Nederland

Completed

A Study for Older Adults With Acute Lymphoblastic Leukaemia (UKALL60+)

Acute Lymphoblastic Leukaemia

United Kingdom, Netherlands
Stichting Hemato-Oncologie voor Volwassenen Nederland
Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG)

Recruiting

A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy (HOVON150AML)

Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts-2

Australia, Austria, Belgium, Estonia, Finland, France, Germany, Ireland, Lithuania, Luxembourg, Netherlands, Norway, Spain, Sweden, Switzerland
Stichting Hemato-Oncologie voor Volwassenen Nederland
German CLL Study Group; Nordic CLL Study Group

Recruiting

Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL (AETHER)

CLL/SLL

Netherlands, Denmark, Belgium, Germany
University Medical Center Groningen
Hoffmann-La Roche; Amsterdam UMC, location VUmc; Stichting Hemato-Oncologie voor...

Withdrawn

Molecular Imaging Using Radiolabeled Atezolizumab to Assess Atezolizumab Biodistribution in Lymphoma Patients

Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

Netherlands
Goethe University
Stichting Hemato-Oncologie voor Volwassenen Nederland; Polish Adult Leukemia... and other collaborators

Terminated

Panobinostat Maintenance After HSCT fo High-risk AML and MDS

Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukaemia (AML)

Germany, Netherlands
Rigshospitalet, Denmark
Karolinska Institutet; Academisch Medisch Centrum - Universiteit van Amsterdam... and other collaborators

Recruiting

Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early Treatment

CLL

Denmark, Sweden, Netherlands
European Organisation for Research and Treatment...
Stichting Hemato-Oncologie voor Volwassenen Nederland; Lymphoma Trials Office

Terminated

Chemotherapy Plus Interferon Alfa Alone or With Radiation Therapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma

Lymphoma

United Kingdom, Netherlands
Erasmus Medical Center
ZonMw: The Netherlands Organisation for Health Research and Development; Stichting...

Recruiting

Azole-echinocandin Combination Therapy for Invasive Aspergillosis (IA-DUET)

Invasive Aspergillosis

Belgium, Netherlands
Stichting Hemato-Oncologie voor Volwassenen Nederland
Astellas Pharma Global Development, Inc.; Deutsch-Österreichische Studiengruppe...

Active, not recruiting

A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML)

Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts-2

Netherlands, Belgium, Germany, Switzerland, Australia, Finland, Norway, Sweden, Austria, France, Ireland, Lithuania, Luxembourg, Spain
Stichting Hemato-Oncologie voor Volwassenen Nederland
UMC Utrecht; Amsterdam University Medical Centers; The Dutch Network for Cardiovascular...

Not yet recruiting

Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma (HO170DLBCL)

DLBCL - Diffuse Large B Cell Lymphoma

Netherlands
Stichting Hemato-Oncologie voor Volwassenen Nederland
European Myeloma Network; Gruppo Italiano Malattie EMatologiche dell'Adulto; DSMM... and other collaborators

Active, not recruiting

Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma (HO95)

Multiple Myeloma

Sweden, Norway, Italy, Netherlands, Belgium, Switzerland, Australia, Denmark, Finland, Czechia, Turkey, Austria, Luxembourg, Hungary, Greece, Portugal
European Organisation for Research and Treatment...
NCIC Clinical Trials Group; Stichting Hemato-Oncologie voor Volwassenen Nederland and other collaborators

Completed

Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

Lymphoma

France, Netherlands, United Kingdom, Australia, Canada, Norway, Poland, Belgium, Italy, New Zealand, Denmark, Egypt, Hungary, Portugal, Slovakia, Slovenia, South Africa, Sweden
German CLL Study Group
Cancer Trials Ireland; Stichting Hemato-Oncologie voor Volwassenen Nederland... and other collaborators

Active, not recruiting

Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL) (CLL17)

Chronic Lymphoid Leukemia

Spain, Ireland, Austria, Denmark, Israel, Norway, Germany, Switzerland, Italy, Belgium, Finland, Sweden, Netherlands
German CLL Study Group
AbbVie; Hoffmann-La Roche; Swiss Group for Clinical Cancer Research; Stichting... and other collaborators

Completed

Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation (GAIA)

Chronic Lymphocytic Leukemia

Ireland, Germany, Israel, Austria, Belgium, Denmark, Switzerland, Finland, Sweden, Netherlands

Clinical Trials Sponsored by Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations